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We report a case of Zika virus infection imported in 
Florence, Italy ex-Thailand, leading to a secondary 
autochthonous case, probably through sexual trans-
mission. The two cases occurred in May 2014 but 
were retrospectively diagnosed in 2016 on the basis 
of serological tests (plaque reduction neutralisation) 
performed on stored serum samples. Our report pro-
vides further evidence that sexual transmission of 
Zika virus is possible.
Case reports
At the beginning of May 2014, an Italian man is his 
early 30s (patient 1) returned to Florence, Italy, after a 
10-day holiday in Thailand. On the day after his arrival, 
he developed a confluent maculopapular rash, on the 
face, trunk, arms, and legs, with fever (maximum tem-
perature 38 °C), conjunctivitis, and frontal headache 
with retroocular pain.
Four days later, patient 1 was admitted to the Infectious 
and Tropical Diseases Unit of the Florence Careggi 
University Hospital. Blood tests revealed leucopenia 
(3,000 cells/µL; reference: 4,000–10,000/µL) while 
creatinine, platelet count and transaminases were 
normal. Serological investigation two days after (i.e. 
6 days after symptoms onset), showed past exposure 
to measles and parvovirus, negative results for human 
immunodeficiency virus (HIV) 1–2 Ab/Ag and chikungu-
nya IgM, a positive result for dengue virus (DENV) IgM, 
and negative results for DENV IgG, as well as DENV NS1 
Ag (Table). 
The symptoms subsequently rapidly resolved (total 
duration of fever and rash: 6 days) and he was dis-
charged nine days after admission with a probable 
diagnosis of DENV infection. 
Perifocal vector control activities (including spraying 
adult mosquitoes and destruction of larval breeding 
sites) were implemented the day after the availability 
of DENV IgM positive results, around the patient’s resi-
dence and workplace, even though the period of activ-
ity of Aedes albopictus in Italy is usually considered to 
start in June and end in October [1]. A second and third 
blood test using enzyme-linked immunosorbent assay 
(ELISA), performed 38 and 109 days after symptoms 
onset, showed DENV IgG seroconversion and IgM nega-
tivisation in the third sample.
Nineteen days after the onset of symptoms in patient 
1, his girlfriend (patient 2), who was in her late 20s 
developed diffuse pain, associated to both wrists and 
oedema on fingers of each hand, maculopapular rash 
on the trunk, arms, and legs, without fever. Four days 
later she was evaluated at the outpatient facility of the 
same hospital. Patient 2 had not travelled to tropical 
areas during the previous year. Blood tests performed 
on the next day (5 days after her symptoms started) 
showed normal white blood cells and platelet count, 
normal C-reactive protein, creatinine, transaminases, 
and undetectable beta-human chorionic gonadotro-
pin (HCG). The patient had IgG antibodies against 
cytomegalovirus, Epstein–Barr virus, parvovirus and 
rubella, while she was seronegative for coxsackie A, 
coxsackie B, echovirus and DENV (IgG, IgM and NS1 
Ag). Serological tests were repeated 39 and 93 days 
after symptoms onset, respectively, showing a slight 
positivity for DENV IgG, with IgM and NS1Ag persis-
tently negative (Table).
Retrospective testing of serum samples in 
2015 and 2016
Serum samples of both patients were sent to the Istituto 
Superiore di Sanità (ISS), Rome, Italy, to perform con-
firmatory tests (Table) for DENV in June and September 
2015, respectively. Plaque reduction neutralisation 
tests (PRNTs) for DENV gave inconclusive results for 
both patients: indeed, a 50% of plaque reduction was 
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observed at a 1:10 serum dilution in the second and 
third serum samples of both patients, while we con-
sider the cut-off for a positive result to be at least 80% 
of plaque reduction. Real-time polymerase chain reac-
tion (PCR) tests for DENV, chikungunya virus (CHIKV), 
and Zika virus (ZIKV), as well as viral isolation in Vero 
E6 cell, were also performed on samples collected 
in the acute phase of the disease, all with negative 
results.Even though DENV PRNT results were inconclu-
sive, patient 1 was counselled as having had dengue 
infection, given the history of travel and the classical 
kinetic of IgG and IgM antibodies measured by ELISA, 
while we were not able to state a definitive diagnosis 
for patient 2.After ZIKV for PRNT became available to 
us, the samples were reanalysed in February 2016 (the 
patients had given their informed consent for further 
tests), and showed positive results for ZIKV neutralis-
ing antibodies, as reported in the Table, with a clear 
increase in the antibody titre between the first and the 
second serum sample for both patients.
Background
ZIKV is an Aedes-borne virus (Flaviviridae family), 
identified in 1947 in monkey rhesus in Uganda [2,3]. 
Sporadic human cases were reported in Asia and 
Africa until 2007, when a ZIKV outbreak occurred in 
Yap, Micronesia [4]. Subsequently, in October 2013, 
ZIKV reached French Polynesia, causing a large out-
break [5]. In early 2015, autochthonous cases of ZIKV 
were reported in Brazil [6], and the virus subsequently 
spread throughout South America, Central America, 
and the Caribbean [7-9]. An increasing number of 
imported cases has been observed in Europe and 
United States (US) [10-13]. The presumed association 
of ZIKV infection during pregnancy with increased 
number of babies born with microcephaly in Brazil [14] 
convinced the World Health Organization to declare 
ZIKV a ‘Global Emergency of Public Health Concern’ in 
February 2016 [15].
Discussion and conclusions
Even if ZIKV transmission is mostly vectorial, transpla-
cental and perinatal transmission have been reported; 
transmission through blood transfusion may also occur 
[16-18].
Little evidence supports the possibility of ZIKV sexual 
transmission to date. In December 2013, ZIKV was 
isolated from the semen of a patient with haemato-
spermia in Tahiti [19]. Further in 2014, ZIKV RNA was 
detected 62 days after onset of febrile illness in the 
semen of a person with ZIKV infection, imported into 
the United Kingdom from the Cook Islands [20]. Sexual 
transmission from a man who acquired ZIKV infection 
in Senegal, to his wife was reported in Colorado, US, 
in 2007 [21], and more recently from a person who had 
travelled to Latin America, to his partner in Texas [22].
Possible sexual transmission of ZIKV is of particular 
concern during pregnancy, and specific guidelines for 
prevention of ZIKV infection through this route have 
been published recently [23].
Because patient 2 had not travelled to tropical areas 
during the previous year and had unprotected sex-
ual intercourse with patient 1 during a 20 day period 
between his return to Italy and her own onset of symp-
toms, transmission by semen was suggested. Exact 
dates of sexual intercourse could not be recalled by the 
patients, who reported several sexual contact events 
before patient 2’s symptom onset. Other transmission 
modalities (i.e. direct contact with other bodily fluids) 
Table
Laboratory diagnostic test results for dengue virus and Zika virus in two patients, Italy, 2014–2016
Patient Days from onset of symptoms 









a,c titre Real-time PCRa,c PRNT80
c,d titre Real-time PCRa,c 
1
6 24.2 5.21 2.23 2.01 Neg Neg 1:10 Neg
38 12.3 16.6 NC 2.89 1:10 (b.l.) NC ≥1:160 NC
109 3.23 16.4 1.84 0.87 1:10 (b.l.) NC ≥1:160 NC
2
5 1.34 4.63 3.81 0.46 Neg Neg 1:10 Neg
39 3.23 15.5 2.63 0.40 1:10 (b.l.) NC ≥1:160 NC
93 2.51 13.2 2.77 0.34 1:10 (b.l.) NC ≥1:160 NC
b.l.: borderline; ELISA: enzyme-linked immunosorbent assay; NC: not conducted; Neg: negative; PRNT: plaque reduction neutralisation tests; 
PCR: polymerase chain reaction.
a Test performed in 2014.
b Tests performed at Azienda Ospedaliero Universitaria Careggi, Florence (Italy). Commercial ELISA (VIRCELL Granada-Spain). Reference values 
(index): > 11: positive; 9–11: inconclusive; < 9: negative. Positive results are highlighted in bold.
c Tests performed at the Istituto Superiore di Sanità, Rome (Italy). Commercial IgM-capture ELISA system (Focus Diagnostics dengue Virus IgM 
Capture, DxSelect, California, US). Reference values (index): > 1 : positive; < 1 : negative. Positive results are highlighted in bold. Real-time 
PCRs were conducted on RNA from serum samples, as described in [29] and [30]. Dengue virus for PRNT: serotype 2 dengue virus (New 
Guinea B strain). PRNT80 titres ≥1:10 are considered positive, while PRNT50 titres ≥1:10 are considered as borderline.
d Test retrospectively performed in 2016 on stored samples. Zika virus for PRNT was kindly provided by Dr Isabelle Leparc-Goffart of the 
French National Reference Center on Arboviruses in Marseille. The test was performed as described in detail for tick-borne encephalitis 
virus [31], except that Vero cells were used here.
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are unlikely to play a role but may not be completely 
ruled out.
Transmission through local potentially competent vec-
tors, Ae. albopictus, can likely be excluded consider-
ing that patient 1 came back to Italy outside the usual 
period of vector activity and vector control measures 
were implemented within eight days after his arrival to 
Italy, possibly before the estimated extrinsic incuba-
tion period could be completed [1,24].
Failure to detect viral RNA even in samples collected 
few days after the onset of symptoms, and an early 
detection of ZIKV-specific neutralising antibodies, are 
consistent with previous reports [10,19,25]; however, 
limits in the sensitivity of the real-time PCR method 
used in this study cannot be definitively excluded. 
Serological test results confirm the broad cross-reac-
tivity between DENV and ZIKV. With respect to PRNT 
results, borderline results for DENV are likely to be due 
to a low degree of residual cross-reactivity which may 
not be eliminated even using this test, which is consid-
ered highly specific. Another possible limit of our study 
consists in the fact that only serotype 2 DENV PRNT 
could be performed; however, this is not likely to affect 
the interpretation of the results, which clearly show a 
pattern consistent with ZIKV infection.
Current evidence supports the combined use of PCR 
and serological tests for the diagnosis of ZIKV infec-
tion. PCR can be positive in early serum and saliva 
samples (< 8 days after symptoms onset), with saliva 
showing higher detection rates, while PCR on urine 
seems to enlarge the window of detection of ZIKV RNA 
up to ca 30 days after symptoms onset [26,27]. Five 
days after disease onset, serological investigations 
can be conducted by detection of ZIKV-specific IgM 
antibodies and confirmation by neutralisation [28].
In conclusion, we provide additional evidence for sex-
ual transmission of ZIKV. Further studies are needed 
to estimate the probability of sexual transmission and 
its role as a secondary route of transmission of ZIKV in 
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